Edition:
United Kingdom

Biotechnology & Medical Research

Page 1

Doxa Q3 net loss at SEK 2.3 million

7:30am BST

Oct 20 (Reuters) - Doxa Ab ::Q3 net sales sek ‍3.4​ million versus sek 4.0 million year ago.Q3 net loss sek ‍2.3​ million versus loss sek 2.9 million year ago.

PledPharma Q3 net loss widens to SEK ‍​27.3 million

7:00am BST

Oct 20 (Reuters) - PLEDPHARMA AB (PUBL) ::Q3 NET LOSS SEK ‍​27.3 MILLION VERSUS LOSS SEK 7.9 MILLION YEAR AGO.

ThromboGenics cash and investments up at 113.4 million euros

6:30am BST

Oct 20 (Reuters) - THROMBOGENICS NV ::CASH AND INVESTMENTS €113.4 MILLION AS OF END OF SEPT. 2017 VERSUS €65.1 MILLION AT END OF JUNE 2017‍​.ANNOUNCES NOVARTIS WILL INVEST €10 MILLION IN THROMBOGENICS CAPITAL.

BB Biotech Q3 net profit down at CHF 365 million

6:00am BST

Oct 20 (Reuters) - BB BIOTECH AG ::PRODUCT APPROVALS AND SOLID COMPANY RESULTS LEAD THE BIOTECH SECTOR HIGHER.Q3 ‍NET PROFIT AMOUNTED TO CHF 365 MN VERSUS PROFIT OF CHF 392 MN REPORTED IN Q3 LAST YEAR​.

Ignyta says public offering of 10.0 million common shares priced at $16.00per share

2:01am BST

Oct 19 (Reuters) - Ignyta Inc ::Ignyta announces pricing of public offering of common stock.Says public offering of 10.0 million common shares priced at $16.00per share.

Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint

Thursday, 19 Oct 2017

Oct 20 (Reuters) - Durect Corp :Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint.Durect Corp - ‍phase 3 clinical trial for Posimir(®) (saber(®)-bupivacaine), did not meet its primary efficacy endpoint​.Durect Corp - results from phase 3 clinical trial for Posimir​ trended in favor of Posimir versus comparator, but did not achieve statistical significance.

Biopharmx files for offering ‍​of up to $40.3 mln of shares of common stock

Thursday, 19 Oct 2017

Oct 20 (Reuters) - Biopharmx Corp :Biopharmx Corp files for offering ‍​of up to $40.3 million of shares of common stock - SEC filing.

Neurocrine Biosciences says David-Alexander Gros resigns as COO and interim CFO of co

Thursday, 19 Oct 2017

Oct 20 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences Inc - ‍on Oct. 18, David-Alexander C. Gros resigned as president, COO and interim CFO of co, effective as of Oct. 19 - SEC filing.Neurocrine Biosciences Inc - ‍in connection with resignation of Gros, effective Oct. 19, Kevin C. Gorman​ was appointed as company's interim CFO.

MabVax Therapeutics files for resale of up to 6.97 mln shares of co's common stock‍​

Thursday, 19 Oct 2017

Oct 20 (Reuters) - MabVax Therapeutics Holdings Inc :MabVax Therapeutics Holdings Inc files for resale of up to 6.97 million shares of co's common stock‍​ by the selling stockholders - SEC filing‍​.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary